EY
EyePoint Pharmaceuticals, Inc.
EYPT · NASDAQ
$3.17 +0.63% (+$0.02)
1M -30.92%
Market Cap $264.1M
P/E Ratio -
Div. Yield -
ROE 135.81%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
49 /100
Fair P/B 1.59x
P/S 94.69x
PEG N/A
Growth
22 /100
Declining Book val. growth 47.00%
Rev. growth 8.83%
FCF growth N/A
Profitability
17 /100
Weak FCF margin 9,726.75%
Op. margin 11,365.20%
Gross margin 41.77%
Quality
0 /100
Poor Asset turnover 0.01x
ROA 134.38%
ROIC 167.81%
Debt
100 /100
Low Current ratio 4.50x
Debt/Equity 0.13x
Net debt/EBITDA N/A
Stability
39 /100
Moderate Profitable years 0
EPS volatility 38.17%
Beta 1.64x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about EYPT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jay S. Duker
Employees
214
Headquarters
Watertown
Upcoming events
04 NOV
Earnings
Upcoming earnings report